Indiana is currently home to 1251 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Goshen Health, Goshen, Indiana
Conditions: Solid Tumors, GI Cancer
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye
Recruiting
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an opthalmic solution to determine if safe and efficacious for dry eye patients. After a 2-week run-in period, patients will be randomized equally to the PL9643 opthalmic solution or vehicle opthalmic solution administered bilaterally three times a day for 12 weeks. A Data Monitoring Committee will be engaged to review interim data.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2022
Locations: Palatin Clinical Site #6, Carmel, Indiana
Conditions: Dry Eye, Dry Eye Syndromes
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Riley Hospital for Children - Indiana University, Indianapolis, Indiana
Conditions: B-cell Acute Lymphoblastic Leukemia
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Recruiting
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/07/2021
Locations: Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana
Conditions: RLS
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, the PROCEED Study
Recruiting
This study gathers information on patients at different stages of chronic pancreatitis to better understand the natural course and risk factors associated with pancreatitis. Chronic pancreatitis is a disease that occurs when the pancreas is inflamed (swollen and irritated) all of the time. It is important for doctors to diagnose chronic pancreatitis in the beginning stages of the disease. Over time, as chronic pancreatitis gets worse, the pancreas may stop working correctly. Since treatment opti... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2021
Locations: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Acute Pancreatitis, Chronic Pancreatitis
Re-entry Continuum for Brain Injury
Recruiting
The overall research objectives of the proposed project are to decrease the rate of recidivism, defined as returning to incarceration within three years of release, as well as reduce the number of violent offenses, through the successful implementation of a continuum of services that addresses the unique needs of the TBI population. RHI, in partnership with PCF and IU, will work together to accomplish these goals. To meet study objectives, this randomized controlled trial (RCT) will enroll 102 i... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/05/2021
Locations: Putnamville Correctional Facility, Greencastle, Indiana
Conditions: Traumatic Brain Injury, Recidivism
Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
Recruiting
The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily. Colorectal cancer screening tests range from more invasive and very sensitive for polyps and cancer (colonoscopy) to less invasive and less sensitive (e.g., fecal immunochemical testing (FIT)). Screening rates go up when patients consider all these tests, not just colonoscopy. Informing patients about their options for CRC screening could... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2021
Locations: Indiana University, Indianapolis, Indiana
Conditions: Colorectal Cancer Screening
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Brownsburg, Indiana
Conditions: Ulcerative Colitis
MCJR Joint Replacement Clinical Outcomes Database
Recruiting
The purpose of this research study is to develop a database of information regarding the diagnosis, treatment, and outcome of participants who have had a joint replacement. The more information gathered, the better the investigators will be able to treat future patients who need a joint replacement. For example the investigators learn what works well to help design implants and treatment protocols for the future. The investigators publish manuscripts and present research findings around the worl... Read More
Gender:
All
Ages:
All
Trial Updated:
08/31/2020
Locations: Midwest Center for Joint Replacement, Indianapolis, Indiana
Conditions: Joint Replacement
Esophageal Impedance and Manometry Measurements and Dysphagia Symptom Scoring
Recruiting
Comparison of manometry measurements and EndoFlip Balloon measurements in patients with dysphagia and a known esophageal diagnosis
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
08/06/2020
Locations: Indiana University, Indianapolis, Indiana
Conditions: Dysphagia, Esophageal
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Recruiting
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treat... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2020
Locations: Indiana University, Indianapolis, Indiana
Conditions: Newly Diagnosed FLT3 Mutated AML
Pulmonary Hypertension Association Registry
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
All
Ages:
All
Trial Updated:
04/01/2020
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension